X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)
100% of study participants (n=25) achieved robust responses to oral mavorixafor 100% of neutropenic participants…
News
Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial
PURCHASE, N.Y., Sept. 27, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today…
Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial
PURCHASE, N.Y., Sept. 27, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today…
Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage…
Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage…
Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024
Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing…
Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage…
Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024
Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing…
Tavros Therapeutics Raises $7.5 Million in Oversubscribed Seed II Round
Funds to be used to continue developing proprietary platform to rapidly identify synthetically lethal interactions…
Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024
Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing…
Tavros Therapeutics Raises $7.5 Million in Oversubscribed Seed II Round
Funds to be used to continue developing proprietary platform to rapidly identify synthetically lethal interactions…
IN8bio to Present at Cantor Oncology & HemOnc Conference
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
Tavros Therapeutics Raises $7.5 Million in Oversubscribed Seed II Round
Funds to be used to continue developing proprietary platform to rapidly identify synthetically lethal interactions…
IN8bio to Present at Cantor Oncology & HemOnc Conference
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) — Opus Genetics, a patient-first gene…
IN8bio to Present at Cantor Oncology & HemOnc Conference
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) — Opus Genetics, a patient-first gene…
Mindset Pharma Provides Strategic Intellectual Property License to Cybin
Licensing Subset of Mindset’s Family 1 Intellectual Property Underscores Strength of Mindset’s Portfolio and Business…
Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) — Opus Genetics, a patient-first gene…
Mindset Pharma Provides Strategic Intellectual Property License to Cybin
Licensing Subset of Mindset’s Family 1 Intellectual Property Underscores Strength of Mindset’s Portfolio and Business…